LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

LLY

1,014.2

-2.5%↓

JNJ

203.5

-1.16%↓

ABBV

229.23

+0.8%↑

UNH

334.19

+0.48%↑

AZN

90.44

-0.75%↓

Inicio・Lista de Acciones・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Abierto

SectorSanidad

22.84 -0.95

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

22.45

Máximo

23.23

Métricas clave
By Trading Economics
Ingresos	675K 53M
Ventas	1.8M 148M
P/B Media del Sector	13.269 80.03
Margen de beneficios	35.57
Empleados	181
EBITDA	1.7M 80M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+47.19% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	165M 2.8B
Apertura anterior	23.79
Cierre anterior	22.84

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

101 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

N/A / 24.28 Soporte y Resistencia

Catalyst Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

3 dic 2025, 23:21 UTC

Ganancias

Adquisiciones, fusiones, absorciones

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dic 2025, 23:14 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dic 2025, 22:01 UTC

Principales Movimientos del Mercado

Costco Wholesale Reports Higher Monthly Sales

3 dic 2025, 21:38 UTC

Ganancias

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dic 2025, 23:59 UTC

Charlas de Mercado

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dic 2025, 23:49 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dic 2025, 23:13 UTC

Charlas de Mercado

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dic 2025, 23:10 UTC

Ganancias

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dic 2025, 23:08 UTC

Charlas de Mercado

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dic 2025, 23:06 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dic 2025, 22:59 UTC

Adquisiciones, fusiones, absorciones

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dic 2025, 22:45 UTC

Charlas de Mercado

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dic 2025, 22:20 UTC

Ganancias

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dic 2025, 22:19 UTC

Ganancias

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dic 2025, 22:17 UTC

Ganancias

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dic 2025, 22:16 UTC

Ganancias

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dic 2025, 22:15 UTC

Ganancias

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dic 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dic 2025, 22:09 UTC

Adquisiciones, fusiones, absorciones

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dic 2025, 21:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

3 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

3 dic 2025, 21:49 UTC

Ganancias

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:23 UTC

Ganancias

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dic 2025, 21:19 UTC

Ganancias

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:06 UTC

Ganancias

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:04 UTC

Ganancias

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dic 2025, 21:04 UTC

Ganancias

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dic 2025, 21:03 UTC

Ganancias

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Comparación entre iguales

Cambio de precio

Catalyst Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

47.19% repunte

Estimación a 12 Meses

Media 34 USD 47.19%

Máximo 35 USD

Mínimo 33 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Catalyst Pharmaceuticals Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

N/A / 24.28Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Sentimiento

By Acuity

101 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.